The Effect of PDE5 Inhibitors on the Male Reproductive Tract

Author(s): Nikolaos Sofikitis*, Aris Kaltsas, Fotios Dimitriadis, Jens Rassweiler, Nikolaos Grivas, Athanasios Zachariou, Apostolos Kaponis, Panagiota Tsounapi, Napoleon Paterakis, Andreas Karagiannis, Sotirios Skouros, Ioannis Giannakis, Ioannis Champilomatis, Minas Paschopoulos, Diamantis Daphnis, Ioannis Giakoumakis, Melinda R.Gabales, Jo Ben M. Chua, Pedro L. Lantin III, Charalampos Mamoulakis, Atsushi Takenaka

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 23 , 2021

Become EABM
Become Reviewer
Call for Editor


The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig and Sertoli cells secretory function. It also appears that PDE5 inhibitors play a role in the regulation of the contractility of the testicular tunica albuginea and the epididymis. Moreover, scientific data suggest that PDE5 inhibitors enhance the prostatic secretory function leading to an improvement in sperm motility. Other studies additionally demonstrate the role of PDE5 inhibitors in the regulation of the sperm capacitation process. Placebo-controlled, randomized, blind studies are necessary to unambiguously incorporate PDE5 inhibitors as an adjunct tool for the pharmaceutical treatment of semen disorders and male infertility.

Keywords: Spermatozoa, testis, epididymis, phosphodiesterase, prostate, seminal vesicles, PDE5 inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 26 February, 2020
Page: [2697 - 2713]
Pages: 17
DOI: 10.2174/1381612826666200226121510
Price: $65

Article Metrics

PDF: 243